Aims: Using a pragmatic approach, the LIRA-PRIME trial aims to address a knowledge gap by comparing efficacy in controlling glycaemia with glucagon-like peptide-1 analog liraglutide vs oral antidiabetic drugs (OADs) in patients with type 2 diabetes (T2D) uncontrolled with metformin monotherapy in primary care practice. We report the study design and patient baseline characteristics.
glycaemic control for several years before treatment is intensified, 3 in part because of fears associated with treatment-associated weight gain and hypoglycaemia, and also because patients may perceive more advanced treatment regimens to be too complex or burdensome. 4 Furthermore, delay may be the result of clinical inertia.
Although the burden of care of patients with T2D generally falls within the realm of primary care, 5 there remains a lack of evidence from randomized trials to guide clinical decision-making in this setting.
Randomized clinical trials conducted in specialist settings are often characterized by narrow inclusion criteria and strictly controlled interventions that require high compliance with study protocol. Translating results from these trials into general clinical practice can be challenging. Pragmatic trials in a primary care setting are associated with broader inclusion criteria and more loosely defined interventions, thereby providing clinical evidence that is more generalizable to a daily clinical care setting. [6] [7] [8] Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as liraglutide, are recommended as a second-line treatment option when metformin monotherapy is considered insufficent. 1 Randomized controlled trials have demonstrated clinically significant reductions in glycated haemoglobin (HbA1c) with liraglutide, along with weight loss and low risk of hypoglycaemia, in patients with T2D as compared with other antidiabetic treatment regimens. [9] [10] [11] [12] Additionally, a large cardiovascular (CV) outcomes trial, LEADER, reported a significant reduction in the risk of major CV events, all-cause mortality and renal outcomes with liraglutide vs placebo, both in addition to standard of care, in patients with T2D who are at high CV risk. 13, 14 However, no dedicated randomized pragmatic trial with liraglutide has been conducted in the primary care setting, and the efficacy of liraglutide in maintaining glycaemic control in patients inadequately controlled with metformin in primary care practice, as compared with other available OADs, is unknown. A durable, dual glucose-lowering treatment regimen that keeps pace with disease progression without necessitating frequent regimen changes in this setting would be beneficial to both patients and healthcare providers.
Using a pragmatic approach, the LIRA-PRIME trial aims to add valuable evidence to bridge this knowledge gap by comparing efficacy in controlling glycaemia with liraglutide vs OADs in patients with T2D
who are uncontrolled with metformin monotherapy in primary care
practice. This manuscript describes the study design and operational aspects, and provides baseline data for the trial population.
| MATERIALS AND METHODS

| Study design and participants
The LIRA-PRIME trial (ClinicalTrials.govNCT02730377) is a 104-week, multi-centre, randomized, two-arm, open-label, active-controlled clinical trial, conducted in the primary care setting. In this trial, the term "primary care" was adapted from the definition used by the American Academy of Family Physicians. 15 The trial has a pragmatic design to reflect diabetes management in primary care: a low number of eligibility criteria allowing enrollment of a broad patient population, treatments prescribed according to local labels, quarterly patient visits, and trial products dispensed by retail pharmacies. The trial is scheduled for completion in August 2019. Inclusion and exclusion criteria are presented in Table 1 .
The LIRA-PRIME trial is being conducted in compliance with
Good Clinical Practice (International Conference on Harmonization) and applicable regulatory requirements including Institutional Review
Board approval 16 and in accordance with the Declaration of Helsinki. 17 Informed consent was obtained from all patients before any trial-related activity. All patients have the right to withdraw from the trial at any time, without giving a specific reason.
| Randomization and masking
After an initial screening period of up to 2 weeks, during which patients continued usual metformin treatment, patients were randomly assigned than 7.0%; however, escalation to the maximum approved or maximum tolerated dose should be attempted, at the discretion of the investigator if HbA1c is 7.0% or greater. All patients will maintain the same pre-trial dose of metformin during the entire trial, unless there is a safety concern.
Patient visits are scheduled at Weeks 2, 4, 16 and 26 after randomization, and on a quarterly basis thereafter (Table 2) , to reflect the normal frequency of appointments in daily clinical routine. adherence is not measured because of the pragmatic design. As trial products are dispensed by local retail pharmacies, drug accountability is based on the prescribed trial product and empty packaging material returned to the investigator at clinic visits.
| Outcomes
The primary objective of this study is to compare glycaemic control with liraglutide vs that with OADs, both as add-on to metformin without weight gain and no treatment-emergent severe hypoglycaemic episodes or blood glucose-confirmed symptomatic hypoglycaemic episodes.
Safety endpoints include the incidence of hypoglycaemic episodes, serious adverse events, and adverse events leading to permanent discontinuation of the investigational product. Diabetes complications recorded at baseline were reported by the investigator during the screening visit.
| Statistical analyses
The sample size was determined to detect a difference in the time to inadequate glycaemic control (HbA1c >7.0%) between the liraglutide and OAD groups with 90% power. Based on previous clinical trials, 12, 20 the proportion of patients expected to discontinue treatment prematurely without inadequate glycaemic control is 20%. Of the remaining patients, it is expected that 66% in the liraglutide group and 76% in the OAD group will have met the criteria for inadequate glycaemic control by Week 104. However, it is assumed that the Informed consent X pressure, sitting
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With these assumptions, we calculated that 1994 randomized patients are required to ensure sufficient statistical power.
The time to inadequate glycaemic control will be compared between the liraglutide and OAD treatment groups using a two-sided non-parametric log rank test at a 5% significance level. The analysis will not be based on any model assumptions and it will not be adjusted for any covariates; this conservative approach means that any potential bias of baseline characteristics will be towards no treatment effect.
The full analysis set includes all randomized patients and will be used in the analysis of the primary endpoint and other efficacy endpoints.
Statistical evaluation of the full analysis set will follow the intentionto-treat principle, with patients contributing to the evaluation as ran- 
| RESULTS
Between 28 March 2016 and 7 August 2017, the LIRA-PRIME trial enrolled 1997 patients from 219 sites across nine countries (Figure 2 ).
Baseline patient demographics and clinical characteristics are summarized in Table 3 .
Patients presented with a wide range of diabetes duration, from less than 1 year to 47 years, and macro-angiopathy (3.1%).
| DISCUSSION
Although improved glycaemic control with liraglutide in patients with T2D has been extensively assessed in specialist care settings, 21 little is known about the treatment effect in the setting of routine primary care. With a pragmatic design, a more heterogeneous population at baseline than most randomized clinical trials in specialist care, and a number of treatment options compared in this study, the LIRA-PRIME trial should provide further guidance for optimal treatment of patients with T2D who are managed in primary care practice. The wide ranges of baseline data and clinical characteristics collected reflect the primary care setting. 22 While pragmatic trials conducted in diverse primary care settings around the world contribute to addressing the lack of data concerning primary care, they also present certain challenges. One challenge is to define endpoints and outcomes that are relevant to patients. These should be simple and should be assessed by procedures/methods widely available in clinical practice, without compromising quality and consistency. The primary endpoint in the LIRA-PRIME trial is relevant to patients' daily care and reflects the questions concerning choice of the treatment that is most likely to be able to keep pace with disease progression. This concern is not likely to be addressed in randomized trials of short duration, for example, 6 months.
Another challenge in the LIRA-PRIME trial derives from the simple inclusion criteria for HbA1c. Patients were included in the trial based on HbA1c values between 7.5% and 9.0%, measured within 90 days prior to screening at a local laboratory and documented in the medical records; however, one quarter of the patients at randomization had HbA1c values below 7.5% or above 9.0% as measured by the central laboratory. Discrepancies between the screening HbA1c to less than 7.0% will be more difficult in patients with HbA1c above 9.5% than in those with HbA1c below 9.0%. This could potentially affect the number and timings of premature withdrawals due to inadequate glycaemic control. However, given that randomization should have resulted in a fairly even distribution of participants with baseline HbA1c values outside the permitted range between the liraglutide and OAD groups, this effect should be similar in both arms.
Advertising for trial participants is a standard method used in most clinical trials to ensure that recruitment timelines are met.
Because of the pragmatic approach of this trial and the primary care setting, patients were informed about the trial only at the level of the local clinic, through posters and direct conversation with physicians;
however, recruiting a sufficient number of participants without a broader advertising campaign proved more difficult than anticipated.
Thus, the recruitment period was extended from 12 to 18 months to allow sufficient time for physicians to recruit from their own patient
populations. An important element of the pragmatic trial design was to have patients obtain trial products directly from a local retail pharmacy, but this requires different methods of reimbursement in each participating country, to conform with local regulations.
To obtain valid results, a certain extent of intervention was needed in the LIRA-PRIME trial to achieve sufficient patient adherence to the protocol. Although the intent of the trial design was for patients to receive the maximum approved or tolerated dose as early as possible, the pragmatic design gave investigators the option of escalating the dose at their discretion to minimize side effects (eg, gastrointestinal adverse events). Although this discretion could introduce some clinical inertia within the trial, it may be balanced by increased adherence as the result of fewer side effects and regular follow-up physician visits. We recognize that there are limitations to the trial design. For example, physician selection of OAD can be influenced by the knowledge that the efficacy of these agents is being compared with that of a GLP-1RA, potentially leading physicians to select a more potent agent than usual, and influenced also by the external funding of treatment, which potentially removes cost considerations from treatment decisions. Both of these factors could lead to treatment practices that do not reflect those of the everyday clinical setting. Another limitation is that, to closely mimic real-world management, treatment adherence was not monitored. It is possible that the hypoglycaemia and weightloss benefits may favour adherence to liraglutide, 23 potentially biasing treatment outcomes; however, the injection regimen of liraglutide and its early gastrointestinal side effects, 24 which are not present with other OADs used in this study, with the exception of DPP-4is, might disfavour adherence in patients treated with liraglutide, thus biasing treatment outcomes in the opposite direction. Finally, a third limitation, which may be intrinsic to any trial, is that the updating of treatment guidelines and the emergence of new standards of care may render the study treatment(s) sub-optimal in certain scenarios; however, because of the open-label design of the LIRA-PRIME trial, investigators are aware of the drug a patient is receiving and participants can be withdrawn from the study at any time, should there be any safety concerns.
23
In summary, the LIRA-PRIME trial has successfully enrolled the desired number of patients (n = 1997) from 219 primary care practices across nine countries. The demographic and clinical profiles of these individuals suggest that they represent a heterogeneous group.
Primary care physicians will soon have comparative data concerning the safety and efficacy of liraglutide as compared to OADs within a primary care setting for patients not reaching glycaemic targets with metformin alone. Results of the trial should be available in 2020.
